Paper42885307PubMed
Resveratrol alleviates osteoarthritis progression by inhibiting NLRP3 inflammasome response via the AMPK/PPARγ signaling pathway.
Cui S and 7 others. Int J Mol Med, 2026.
Cite this record
ConductScience Library. Resveratrol alleviates osteoarthritis progression by inhibiting NLRP3 inflammasome response via the AMPK/PPARγ signaling pathway. Papers, record 42885307. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42885307
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Resveratrol alleviates osteoarthritis progression by inhibiting NLRP3 inflammasome response via the AMPK/PPARγ signaling pathway.
- Journal
- Int J Mol Med
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-29
Source PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| NLR Family, Pyrin Domain-Containing 3 Protein | Major topic |
| Resveratrol | Major topic |
| Osteoarthritis | Major topic |
| PPAR gamma | Major topic |
| Inflammasomes | Major topic |
| AMP-Activated Protein Kinases | Major topic |
| Signal Transduction | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Male | |
| Disease Progression |
Source PubMed
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40896702 | Resveratrol as a naturally occurring inflammasome modulator: Implications for health and disease. | Iran J Basic Med Sci | 2025 | https://conductscience.org/library/papers/40896702 | PubMed |
| 2 | 38229660 | The IRF1/GBP5 axis promotes osteoarthritis progression by activating chondrocyte pyroptosis. | J Orthop Translat | 2024 | https://conductscience.org/library/papers/38229660 | PubMed |
| 3 | 33936363 | Effect of resveratrol on abnormal bone remodeling and angiogenesis of subchondral bone in osteoarthritis. | Int J Clin Exp Pathol | 2021 | https://conductscience.org/library/papers/33936363 | PubMed |
| 4 | 39376171 | The role and current research status of resveratrol in the treatment of osteoarthritis and its mechanisms: a narrative review. | Drug Metab Rev | 2024 | https://conductscience.org/library/papers/39376171 | PubMed |
| 5 | 34917160 | Identification of the Resveratrol Potential Targets in the Treatment of Osteoarthritis. | Evid Based Complement Alternat Med | 2021 | https://conductscience.org/library/papers/34917160 | PubMed |
| 6 | 40502812 | Resveratrol: Molecular Mechanisms, Health Benefits, and Potential Adverse Effects. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40502812 | PubMed |
| 7 | 16978198 | Synovitis score: discrimination between chronic low-grade and high-grade synovitis. | Histopathology | 2006 | https://conductscience.org/library/papers/16978198 | PubMed |
| 8 | 33805920 | Establishing SW1353 Chondrocytes as a Cellular Model of Chondrolysis. | Life (Basel) | 2021 | https://conductscience.org/library/papers/33805920 | PubMed |
| 9 | 32156705 | Metformin limits osteoarthritis development and progression through activation of AMPK signalling. | Ann Rheum Dis | 2020 | https://conductscience.org/library/papers/32156705 | PubMed |
| 10 | 38890638 | Cartilage progenitor cells derived extracellular vesicles-based cell-free strategy for osteoarthritis treatment by efficient inflammation inhibition and extracellular matrix homeostasis restoration. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38890638 | PubMed |
| 11 | 37020714 | PPAR-γ Activation Alleviates Osteoarthritis through Both the Nrf2/NLRP3 and PGC-1α/Δψ m Pathways by Inhibiting Pyroptosis. | PPAR Res | 2023 | https://conductscience.org/library/papers/37020714 | PubMed |
| 12 | 25940958 | Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α. | Arthritis Rheumatol | 2015 | https://conductscience.org/library/papers/25940958 | PubMed |
| 13 | 11263774 | Peroxisome proliferator--activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. | Arthritis Rheum | 2001 | https://conductscience.org/library/papers/11263774 | PubMed |
| 14 | 37341015 | Buspirone attenuated methotrexate-induced hippocampal toxicity in rats by regulating Nrf2/HO-1, PPAR-γ, NF-κB/nNOS, and ROS/NLRP3/caspase-1 signaling pathways. | J Biochem Mol Toxicol | 2023 | https://conductscience.org/library/papers/37341015 | PubMed |
| 15 | 22258606 | Inflammasomes in health and disease. | Nature | 2012 | https://conductscience.org/library/papers/22258606 | PubMed |
| 16 | 41793791 | KLK8 promotes cartilage degradation and pyroptosis in osteoarthritis by activating the NF-κB and NLRP3 inflammasome pathways. | Tissue Cell | 2026 | https://conductscience.org/library/papers/41793791 | PubMed |
| 17 | 28989978 | The therapeutic potential of resveratrol: a review of clinical trials. | NPJ Precis Oncol | 2017 | https://conductscience.org/library/papers/28989978 | PubMed |
| 18 | 28627596 | Regulation of type II collagen, matrix metalloproteinase-13 and cell proliferation by interleukin-1β is mediated by curcumin via inhibition of NF-κB signaling in rat chondrocytes. | Mol Med Rep | 2017 | https://conductscience.org/library/papers/28627596 | PubMed |
| 19 | 23333322 | Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. | Pharmacol Ther | 2013 | https://conductscience.org/library/papers/23333322 | PubMed |
| 20 | 30195731 | Smiglaside A ameliorates LPS-induced acute lung injury by modulating macrophage polarization via AMPK-PPARγ pathway. | Biochem Pharmacol | 2018 | https://conductscience.org/library/papers/30195731 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42885307
GET https://conductscience.org/api/papers/v1/42885307/references?page=2